A meningioma is a type of primary brain tumour that develops in the meninges, which are the protective layers of tissue that surround the brain and spinal cord. While they are often referred to as brain tumours, they actually grow from the membranes outside the brain tissue itself, although they can cause symptoms by pressing on the underlying neurological structures. In the United Kingdom, meningiomas are the most common type of primary intracranial tumour, and the vast majority are classified as non-cancerous or low grade. Because these tumours typically grow very slowly, they may not cause noticeable symptoms for many years and are sometimes discovered incidentally during medical imaging for unrelated issues. The UK healthcare system utilise a structured approach to managing meningiomas, ranging from active surveillance to surgical intervention, depending on the tumour’s size, location, and grade. Understanding the biological nature of the meninges and the standardised grading system used by the NHS provides a clear framework for patients navigating a diagnosis. By following evidence-based protocols established by NICE, medical teams aim to manage the condition while prioritising the preservation of neurological function and long-term wellbeing.
What We’ll Discuss in This Article
- The biological origin of meningiomas within the protective layers of the brain.
- The standardised World Health Organization (WHO) grading system for meningiomas.
- Common symptoms associated with the compression of brain tissue.
- Known risk factors and the demographic prevalence of these tumours in the UK.
- The diagnostic process using MRI scans and neurological examinations.
- Integrated management pathways, including active surveillance and surgery.
The Biological Origin of Meningiomas
Meningiomas originate from the arachnoid cap cells found in the meninges, the three layers of protective membranes that encase the brain and spinal cord. These layers, consisting of the dura mater, arachnoid mater, and pia mater, serve as a cushion and a framework for blood vessels. The NHS states that a brain tumour is a growth of cells in the brain that multiplies in an abnormal, uncontrollable way.
When these cells begin to divide abnormally, they form a mass that typically grows inward, pushing against the brain or spinal cord rather than invading the tissue directly. Because the meninges cover the entire central nervous system, meningiomas can occur in various locations, such as along the base of the skull or near the optic nerves. In the United Kingdom, pathologists categorise these tumours based on their cellular appearance and their relationship to the surrounding structures. Understanding that most meningiomas are external to the brain tissue itself helps explain why many can be managed successfully with surgery or monitored over long periods without immediate intervention.
The WHO Grading System for Meningiomas
In the United Kingdom, meningiomas are categorised into three grades using the World Health Organization (WHO) system to indicate their likely growth rate and the risk of recurrence. This grading is essential for determining the intensity of clinical follow up and the necessity of active management.
| WHO Grade | Clinical Classification | Typical Behaviour |
| Grade 1 | Benign (low grade) | Slowest growing; lowest risk of return. |
| Grade 2 | Atypical | Faster growing; requires closer monitoring. |
| Grade 3 | Anaplastic (malignant) | Aggressive; most likely to invade tissue. |
NICE clinical guidelines for brain tumours indicate that approximately eighty to ninety per cent of meningiomas are Grade 1, which are considered non cancerous and grow very slowly. Grade 2 and Grade 3 meningiomas are much rarer but require more aggressive management due to their higher growth rate. UK multidisciplinary teams use this grading, alongside the tumour’s location, to decide whether a patient requires immediate surgery or can be safely monitored with regular imaging. This standardised approach ensures that care is proportionate to the specific biological characteristics of the tumour.
Common Symptoms and Clinical Presentation
Symptoms of a meningioma are primarily caused by the tumour pressing on specific parts of the brain or spinal cord as it expands within the rigid confines of the skull. Because these tumours often grow slowly, symptoms may develop so gradually that they are initially attributed to ageing or stress.
The GOV.UK health pages provide clinical profiles indicating that common symptoms of an intracranial mass include persistent headaches, seizures, and changes in vision or hearing. Headaches associated with increased pressure are often worse in the morning and may be accompanied by nausea. Focal symptoms depend on where the meningioma is located; for example, a tumour near the motor cortex might cause weakness in a limb, while one near the frontal lobe could lead to subtle personality changes or memory lapses. In the UK, if these signs are persistent or follow a worsening pattern, they are treated as indicators for urgent neurological investigation.
Risk Factors and Demographics
Meningiomas are most commonly diagnosed in older adults and occur significantly more frequently in women than in men, possibly due to the influence of reproductive hormones on tumour growth. While the exact cause of most meningiomas is unknown, certain established risk factors have been identified by UK health authorities.
Individuals who have previously received high dose ionising radiation to the head, often as part of medical radiotherapy for a different condition, have an increased risk of developing a meningioma later in life. There are also rare genetic conditions, such as Neurofibromatosis Type 2, that predispose individuals to multiple meningiomas. In the United Kingdom, researchers continue to study the role of hormones, as many meningiomas have receptors for progesterone and oestrogen. However, for the majority of patients, the tumour occurs sporadically without a clear external cause. UK clinical teams focus on these evidence-based factors to help identify high risk individuals and guide the diagnostic process.
The Diagnostic Process in the UK
The diagnostic pathway for a suspected meningioma in the United Kingdom involves a thorough neurological examination followed by advanced imaging to confirm the presence and size of the mass. If a patient presents with suspicious symptoms, the GP or hospital specialist will typically order an MRI scan.
An MRI with contrast dye is the preferred diagnostic tool because it provides a detailed view of the meninges and shows how the tumour is interacting with the brain and blood vessels. In some cases, a CT scan may also be used to see if the tumour has caused changes in the nearby bone, as meningiomas can sometimes cause the skull to thicken. The diagnostic process in the UK is coordinated through a multidisciplinary team (MDT), which includes neurosurgeons, radiologists, and oncologists. This team reviews the imaging to determine the most likely grade and to plan the next steps, which may involve a biopsy if the diagnosis is unclear.
Management Pathways for Meningiomas
Management of meningiomas in the United Kingdom is highly individualised and is determined by the tumour’s grade, its size, and whether it is causing symptoms. For many patients with small, slow growing Grade 1 meningiomas that are found incidentally, the clinical team may suggest active surveillance.
The UK management approach includes:
- Active Surveillance: Regularly scheduled MRI scans to monitor the tumour for any changes in size.
- Neurosurgery: Physically removing the tumour, which is often the primary management for symptomatic or large masses.
- Radiotherapy: Using targeted beams of radiation to manage tumours that cannot be fully removed or are higher grade.
- Supportive Care: Using medication to manage specific symptoms like swelling or seizures.
In the UK, the goal of surgery is to remove as much of the meningioma and its attachment to the dura as possible to reduce the risk of it growing back. If a tumour is located in a sensitive area where surgery might be too risky, radiotherapy may be used as an alternative. Throughout the management process, patients are supported by specialist nurses who help coordinate care and provide information on long term recovery. This integrated system ensures that every patient receives a management plan tailored to their specific clinical needs and quality of life goals.
Conclusion
A meningioma is a primary tumour arising from the protective membranes of the brain and is most often low grade and slow growing. In the UK, the NHS provides a clear diagnostic pathway using MRI imaging and manages these tumours through a range of options from active monitoring to surgical removal. While most are non-cancerous, the pressure they exert on the brain requires specialist clinical oversight to prevent neurological complications. Understanding the grade and location of the tumour is essential for determining the best management strategy. If you experience severe, sudden, or worsening symptoms, call 999 immediately.
Is a meningioma always a brain cancer?
Most meningiomas are Grade 1 and are considered benign or non-cancerous, meaning they grow slowly and rarely spread.
Can a meningioma come back after surgery?
Yes, there is a risk of recurrence, which is why UK patients remain under long term follow up with regular scans even after successful removal.
Why do women get meningiomas more often than men?
Research suggests that hormones like progesterone may play a role, as many meningioma cells have receptors for these hormones.
What is “watch and wait” for a meningioma?
This is active surveillance where doctors monitor a stable, asymptomatic tumour with scans rather than performing surgery immediately.
Can a meningioma affect my eyesight?
Yes, if a meningioma is located near the optic nerves or the parts of the brain that process vision, it can cause sight problems.
Are meningiomas hereditary?
Most are sporadic, but they can be linked to rare genetic conditions like Neurofibromatosis Type 2.
How long can I live with a meningioma?
Many people live for decades with a low-grade meningioma, especially if it is slow growing and correctly managed by a clinical team.
Authority Snapshot (E-E-A-T)
This article provides medically factual health education regarding meningioma brain tumours, strictly aligned with NHS and NICE clinical guidelines. The content is developed by a professional medical writing team and reviewed by Dr. Stefan Petrov, a UK-trained physician with experience in surgery, emergency care, and clinical education. All information follows current UK public health protocols to ensure clinical accuracy and patient safety.
